Objective To explore the effects of treatment decision aid on addressing decision-making difficulties and anxiety, depression in patients. Methods Totally 289 patients with lung cancer who were treated in Harbin Medical University Tumor Hospital between July and December 2016 were selected by purposive sampling and randomly divided into treatment group (n=147) and control group (n=142). Patients in the control group received routine guidance and health education from doctors, while patients in the treatment group received decision support manuals and took part in treatment decision-making with medical staff. The Decision Distress Scale and the Hospital Anxiety and Depression Scale were used to assess the intervention effects. Results There was no statistically significant difference between the two groups judging from the scores of the Decision Distress Scale before the intervention (t=0.237, P=0.532). After the intervention, the patients in the treatment group scored lower than the patients in the control group (t=6.437, P<0.001), and there was no statistically significant difference in the level of anxiety (t=0.214, P=0.617) and the level of depression (t=0.105, P=0.874) between the two groups. Conclusions Treatment decision aid can address the decision-making distress and mitigate the sense of uncertainty in patients effectively.

OBJECTIVE To compare the efficacy and safety between the drug winning the bidding for centralized procurement and the original drug of ticagrelor in acute coronary syndrome （ACS） patients one year after percutaneous coronary intervention （PCI）. METHODS Overall 420 ACS patients treated with PCI in our hospital from July 2021 to June 2023 were divided into centralized procurement group （156 cases） and original drug group （264 cases） according to the different varieties of ticagrelor. All patients were given Aspirin enteric-coated tablets 100 mg regularly， once a day； on this basis， patients in the centralized procurement group were given Ticagrelor tablets winning the bidding， while patients in the original drug group were given the original drug of Ticagrelor tablets. The dosage of Ticagrelor tablets taken by both groups of patients was 90 mg， twice a day， and the course of treatment was 12 months. The blood routine indicators were compared before treatment and one week after treatment， while the incidence of net adverse clinical events （NACE）， major adverse cardiovascular and cerebrovascular events （MACCE） and bleeding events， and the survival rate without MACCE and bleeding events during a one-year follow-up after PCI were also compared between two groups. RESULTS There were no statistically significant differences in blood routine indicators before treatment and one week after treatment， as well as the incidence of NACE， MACCE and bleeding events， survival rate without MACCE and bleeding events during a one-year follow-up after PCI between the two groups （P＞0.05）. CONCLUSIONS During a one-year follow-up after PCI， the efficacy and safety of the drug winning the bidding for centralized procurement of ticagrelor are comparable to the original drug.